磁共振脑表面成像在矢状窦旁脑膜瘤术中应用

目的 探讨磁共振脑表面成像技术在矢状窦旁腩膜瘤手术中的应用价值.方法 分析本院经头颅CT及MRI诊断为矢状窦旁脑膜瘤,利用显微手术技术切除并经病理证实的的22例患者;术前均运用磁共振脑表面成像技术评估与肿瘤关系密切的脑表面回流静脉情况.术中根据成像结果有目的 地保护重要的回流静脉,对比患者手术前后神经功能恢复状况,并进行随访来评价手术效果.结果 22例患者的术前磁共振脑表面成像中脑表面回流静脉与术中所见高度一致.术后患者恢复良好,未出现与静脉损伤相关的并发症.结论 磁共振脑表面成像技术能在术前明确矢状窦旁脑膜瘤与脑表面回流静脉之间关系,可在术前对患者肿瘤表面脑回流静脉做出正确的评估,对脑表面重要回流静脉的保护提供了准确的影像学依据,对患者神经功能的保护及术后恢复起到重要作用.     

Repeat Transarterial Chemoembolization (TACE) for Progressive Hepatic Carcinoid Metastases Provides Results Similar to First TACE

Background Transarterial chemoemobolization (TACE) is commonly used to treat metastatic carcinoid tumors; however, the management of progressive disease is less clear. We sought to determine if patients with disease progression after TACE would benefit from repeat TACE. Methods The records of 27 patients undergoing repeat TACE for radiologic or symptomatic progression after TACE for metastatic carcinoid were reviewed and compared to 122 undergoing first TACE. Overall and progression-free survivals were estimated by the Kaplan–Meier method. Results Mean disease-free interval after first TACE was 11.8 months. Radiologic response was observed in 61% compared to 82% after first TACE (p = 0.058); hormone response in 64% compared to 80% (p = 0.159); and symptomatic response in 77% compared to 92% (p = 0.053). The complication rate after repeat TACE was lower than after first TACE (p = 0.03). Median overall survival was similar after repeat (28.1 months) and first TACE (33.3 months) (p = 0.53). Progression-free survival was shorter after repeat TACE but not significantly so. No factor examined could predict survival after repeat TACE. Conclusion Repeat TACE for patients with hepatic carcinoid metastases failing first TACE or having evidence of disease progression is safe and offers a viable treatment option. Presented at the 48th Annual Meeting of The Society for Surgery of the Alimentary Tract, Washington, DC, May, 2007.     

肝动脉解剖变异在肝癌介入治疗中的临床意义

目的探讨肝动脉解剖变异的DSA表现及其在肝癌肝动脉栓塞化疗（TACE）中的临床意义。方法回顾分析223例肝癌患者的DSA资料，对存在解剖变异的肝动脉进一步分析其起源、走行、分布及对TACE的影响，统计每组变异肝动脉的发生率。结果223例中，32例存在肝动脉解剖变异，占14．34％，共40支变异肝动脉，其中变异肝总动脉2支（5％，2／40），变异肝固有动脉1支（2．5％，I／40），变异肝右动脉24支（60％，24／40），变异肝左动脉13支（32．5，13／40），有30支变异肝动脉直接参与肿瘤供血，其中24支行TACE治疗，6支行肝动脉化疗（TAI）。结论正确认识肝动脉的解剖变异特征对提高TACE的成功率、降低手术风险有极其重要的意义。     

脑源性神经生长因子和神经干细胞联合移植对大脑中动脉阻塞大鼠神经功能恢复的作用

目的 将脑源性神经生长因子(BDNF)和神经干细胞(NSCs)单独及联合移植应用于大脑中动脉阻塞(MCAo)模型大鼠,观察BDNF和NSCs移植对大鼠缺血性脑卒中神经功能恢复的作用及BDNF对内源性和外源性NSCs增殖、迁移及分化的影响.方法 体外分离、培养新生大鼠海马NSCs,BrdU标记.实验动物随机分为A组(MCAo组);B组(MCAo+BDNF组);C组(MCAo+NSCs组);D组(MCAo+BDNF+NSCs组),每组16只,移植后进行神经功能损害评分(NSS),用免疫组织化学行BrdU、nestin、BrdU/NSE检测,分析结果.结果 移植后的2、4周神经功能评分分别为:A组5.3±0.5、5.3±0.5;B组4.0±0.8、3.8±0.5;C组3.5±0.6、3.5±0.6;D组2.0 ±0.8、1.8±1.0,D组显著好于其他3组(P<0.05),B组与c组显著好于A组(P<0.05).nes.tin阳性细胞数:A组1.24±1.13,B组2.59±1.44(P<0.05),BrdU阳性细胞数:A组0.52±0.68,B组1.65±1.10(P<0.05).BrdU阳性细胞数:C组6.08±1.52,D组10.26±1.96(P<0.05),BrdU/NSE双阳性细胞数:C组1.74±1.04,D组3.58±1.20(P<0.05).结论 BDNF和NSCs移植单独及联合应用对MCAo大鼠的神经功能恢复均有作用,两者联合具有协同作用.BDNF对内源性NSCs的激活、增殖有促进作用,对外源性NSCs的增殖、迁移及分化有促进作用.     

Treatment strategy for synchronous metastases of colorectal cancer: is hepatic resection after an observation interval appropriate?

Background In cases of synchronous colorectal hepatic metastases, the primary colorectal cancer strongly influences on the metastases. Our treatment policy has been to conduct hepatic resection for the metastases at an interval of 3 months after colorectal resection. We examined the appropriateness of interval hepatic resection for synchronous hepatic metastasis. Materials and methods The subjects were 164 patients who underwent resection of hepatic metastasis of colorectal cancer (synchronous, 70 patients; metachronous, 94 patients). Background factors for hepatic metastasis and postoperative results were compared for synchronous and metachronous cases. Results The cumulative survival rate for 164 patients at 3, 5, and 10 years postoperatively was 71.9%, 51.8%, and 36.6%, and the post-resection recurrence rate in remnant livers was 26.8%. Interval resection for synchronous hepatic metastases was conducted in 49 cases after a mean interval of 131 days. No difference was seen in postoperative outcome between synchronous and metachronous cases. Conclusion The outcome was similarly favorable in cases of synchronous hepatic metastasis and in cases of metachronous metastasis. Delaying resection allows accurate understanding of the number and location of hepatic metastases, and is beneficial in determining candidates for surgery and in selecting surgical procedure.     

介入疗法在急性肢体动脉闭塞治疗中的应用价值

目的探讨介入疗法在急性肢体动脉闭塞治疗中的应用价值。方法回顾性总结28例急性肢体动脉闭塞介入治疗经验。采用经皮血管腔内成形术和动脉内溶栓术治疗上肢动脉闭塞5例、腹主动脉下段闭塞1例、下肢动脉闭塞22例。结果经术后4个月~9年临床观察,急性单段动脉闭塞血管再通率为100%(8/8例)、多段动脉闭塞血管再通率为80%(16/20例),总血管再通率为85.71%(24/28例)。结论介入疗法是治疗急性肢体动脉闭塞的一种有效方法,值得推广应用。     

急性大血管闭塞性轻型卒中血管内治疗的疗效及安全性观察

目的 观察急性大血管闭塞性轻型卒中患者血管内治疗的疗效及安全性。
方法 回顾性分析2018年1月-2019年5月行血管内治疗的急性大血管闭塞性轻型卒中（NIHSS评分
≤5分）患者的临床资料。观察术后血管成功再通率（mTICI≥2b级）、围手术期并发症、90 d良好预后率
（mRS评分≤2分）等。
结果 共纳入13例患者，平均年龄58.7±14.5岁，男性11例（84.6%）。术后血管成功再通率100%；围
手术期并发症2例，假性动脉瘤1例、无症状性颅内出血1例；90 d良好预后率100%。
结论 急性大血管闭塞性轻型卒中行血管内治疗可能是安全、有效的。     

伴肝转移的Ⅳ期胃癌手术方式的合理选择

目的探讨不同手术方式对伴肝转移的Ⅳ期胃癌患者的临床疗效。方法回顾性分析1993-2004年间102例伴肝转移的Ⅳ期胃癌病例的手术方式,评价不同术式对预后的影响。结果肝转移H1的胃癌病例行姑息切除后半年、1年和2年的生存率分别为69%、44%和6%,与改道手术、开腹探查术者的生存率比较,差异有统计学意义(P=0.009)。肝转移H2的胃癌病例姑息切除术后半年、1年和2年的生存率分别为56%、13%和6%,与改道手术、开腹探查术者的生存率比较,差异无统计学意义(P=0.068)。肝转移H3的胃癌病例行姑息切除半年、1年和2年的生存率分别为25%、13%和0,与改道手术、开腹探查术者的生存率比较,差异无统计学意义(P=0.157)。有或无腹膜转移的病例,其术后生存率比较,差异亦无统计学意义(P=0.132)。结论肝转移H1的胃癌患者,无论伴与不伴腹膜转移,均应尽量行姑息性切除手术。肝转移H2、H3的Ⅳ期胃癌患者行切除性手术无益于预后。     

原发性肝癌患者外周血IL-2,sIL-2R,TNFa水平及NK细胞活性检测

目的 :检测原发性肝癌患者外周血IL -2,sIL -2R,TNFa水平及NK细胞活性 ,并探讨患者细胞免疫功能低下的原因。方法 :采用MTT法检测30例原发性肝癌患者外周血单个核细胞白细胞介素2(IL -2)的诱生水平 ;采用ELISA法检测血清可溶性白细胞介素2受体 (sIL -2R) ,肿瘤坏死因子a(TNFa)水平 ;自然杀伤细胞活性 (NK -A)检测采用MTT法。结果 :原发性肝癌患者外周血TNFa水平降低 (P<0.01) ;IL -2、NK -A活性水平低于对照组 (P<0.05) ;sIL -2R水平高于对照组 (P<0.01)。结论 :原发性肝癌患者Th1细胞因子及NK -A活性有所降低 ,检测该指标有助于了解患者机体细胞免疫功能及预后评估。